HTRF Human Phospho-Cyclin D1 (Thr286) Detection Kit, 500 Assay Points

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

HTRF Human Phospho-Cyclin D1 (Thr286) Detection Kit, 500 Assay Points

SDS

IFUs, Manuals & more

This lysate is a component of the Phospho-Cyclin D1 (Thr286) kit. It may be used as a residue-specific positive control for Cyclin D1 phosphorylation.

Product information

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

SDS

IFUs, Manuals & more

Product Variants

partnumber

Part number: 64CYCD1T6PEG

Save to favorites

Unit Size: 500 Assay Points

List price: USD 2,147.00

Your price: Login to view

USD 2,147.00

USD 2,147.00 /each

partnumber

Part number: 64CYCD1T6PEH

Save to favorites

Unit Size: 10,000 Assay Points

List price: USD 12,490.00

Your price: Login to view

USD 0.00

USD 12,490.00 /each

Product information

Overview

This HTRF cell-based assay conveniently and accurately detects phosphorylated Cyclin D1 at Thr286.

Cyclin D family members (including Cyclin D1, Cyclin D2, and Cyclin D3) are important regulators of cell cycle progression. They are integral mediators of growth factor-dependent G1 to S phase progression by playing the role of allosteric regulators of CDK4/6.

Cyclin D1 is upregulated in presence of extracellular mitogenic stimuli, and is then rapidly downregulated by proteasomal degradation following its phosphorylation on Thr286 by the kinase GSK-3β.

Cyclin D1 is an oncogene whose overexpression results in dysregulated CDK4/6 activity and leads to tumorigenesis. Cyclin D1 overexpression may be caused by gene amplification or chromosomal rearrangements, or as a result of impaired degradation of the protein. Mutations and deletions affecting its phosphorylation on Thr286 have been reported in several human cancers.

Specifications

Other Specifications

Application	Protein Detection
Assay Points	500
Assay Target Type	Kit
Assay Technology	HTRF
Automation Compatible	Yes
Brand	HTRF
Detection Method	HTRF
Experimental Type	In vitro
Shipping Conditions	Shipped in Dry Ice
Therapeutic Area	Oncology & Inflammation
Unit Size	500 Assay Points

Video gallery

How it works

Phospho-Cyclin D1 (Thr286) assay principle

The Phospho-Cyclin D1 (Thr286) assay measures Cyclin D1 when phosphorylated at Thr286. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Phospho-Cyclin D1 (Thr286) assay uses 2 labeled antibodies: one with a donor fluorophore, the other with an acceptor. The first antibody was selected for its specific binding to the phosphorylated motif on the protein, the second for its ability to recognize the protein independently of its phosphorylation state. Protein phosphorylation enables an immune-complex formation involving both labeled antibodies, which brings the donor fluorophore into close proximity to the acceptor, thereby generating a FRET signal. Its intensity is directly proportional to the concentration of phosphorylated protein present in the sample, and provides a means of assessing the protein’s phosphorylation state under a no-wash assay format.

Phospho-Cyclin D1 (Thr286) two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a low volume detection plate before adding Phospho-Cyclin D1 (Thr286) HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

Phospho-Cyclin D1 (Thr286) one-plate assay protocol

Detection of phosphorylated Cyclin D1 (Thr 286) with HTRF reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

Assay validation

Validation of Phospho-Cyclin D1 (Thr286) assay specificity by siRNA knockdown experiments

MCF7 cells were plated in a 96-well plate (50,000 cells/well) and cultured for 24h. The cells were then transfected with siRNAs targeting specifically Cyclin D1, Cyclin D2, or Cyclin D3, as well as with a non-targeting siRNA used as negative control. Following a 24h incubation with siRNAs, the medium was renewed for an additional 24h incubation, and the cells were then treated with 10 µM MG132 for 4h. After cell lysis, 16 µL of lysates were transferred into a low volume white microplate and 4 µL of the HTRF Phospho-Cyclin D1 (Thr286) detection antibodies were added to detect Phospho-Cyclin D1 (Thr286). In parallel, 4 µL of the same lysates were transferred into separate wells of the detection plate to detect GAPDH using the HTRF GAPDH Housekeeping assay (Cat # 64GAPDHPEG, 64GAPDHPEH). The HTRF signal was recorded after an overnight incubation for both assays.

Cell transfection with the siRNA targeting Cyclin D1 led to a 80% signal decrease for the Phospho-Cyclin D1 assay compared to the cells transfected with the non-targeting siRNA. On the contrary, the knockdown of Cyclin D2 and Cyclin D3 did not induce any signal decrease. Furthermore, the levels of the housekeeping protein GAPDH were not significantly affected by the treatment with siRNAs, demonstrating that the signal decrease observed for the Phospho-Cyclin D1 assay in presence of Cyclin D1 siRNA was not caused by cell cytotoxicity. Taken together, this data shows that the HTRF Phospho-Cyclin D1 (Thr286) assay is specific for Cyclin D1 and does not cross-react with other Cyclin D family members.

Inhibition of the proteasomal degradation of Cyclin D1 in the presence of MG132

Different cell densities of the human fibrosarcoma cell line HT-1080 were plated in a 96-well culture-treated plate in complete culture medium, and incubated overnight at 37 °C-5% CO2. The cells were treated or not with 10 µM MG132 for 4 hours, and then lysed with 50 µL of supplemented lysis buffer #1 (1X) for 30 minutes at RT under gentle shaking. For the detection step, 16 µL of cell lysate were transferred into a low volume white microplate and 4 µL of the HTRF Phospho-Cyclin D1 (Thr186) or Total Cyclin D1 detection reagents were added. The HTRF signal was recorded after an overnight incubation.

As expected, the levels of Phospho-Cyclin D1 (Thr286) and Total Cyclin D1 increased in the presence of the proteasome inhibitor MG132, which blocks the ubiquitin-dependent proteasomal degradation of the protein and induces its accumulation in the cells.

HTRF phospho-Cyclin D1 (Thr286) assay compared to Western Blot

MCF7 cells were cultured in a T175 flask in complete culture medium at 37°C-5% CO2. After a 48h incubation, the cells were treated with 10 µM MG132 for 4h, and then lysed with 3 mL of supplemented lysis buffer #1 (1X) for 30 minutes at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF Phospho-Cyclin D1 (Thr286) detection reagents. Equal amounts of lysates were used for a side-by-side comparison between HTRF and Western Blot.

Using the HTRF Phospho-Cyclin D1 (Thr286) assay, 3,125 cells/well were enough to detect a significant signal, while 12,500 cells were needed to obtain a minimal chemiluminescent signal using Western Blot. Therefore in these conditions, the HTRF Phospho-Cyclin D1 assay was 4 times more sensitive than the Western Blot technique.